Tuesday, March 21, 2006 3:02:49 PM
CHICAGO, March 21 /PRNewswire/ -- William Blair & Company initiated research coverage of Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) ($46.32) with a Market Perform rating and company profile of Aggressive Growth.
San Diego-based Amylin is focused on the discovery and development of products to treat metabolic disorders -- diabetes in particular.
Analyst John Sonnier estimated that the company would generate revenue of $362 million in 2006, $625 million in 2007, and $866 million in 2008.
"We believe that Amylin is one of the highest-quality midcap biotechnology companies," Sonnier said. "The combination of two first-in-class FDA-approved drugs (Byetta and Symlin), strong management, significant pipeline growth potential, a strong balance sheet, and a partnership with Eli Lilly
distinguishes Amylin among its peers, in our view."
"We expect GLP-1-related therapies to reshape the management of diabetes," he added. "GLP-1 has proved to be a unique metabolic target for managing type 2 diabetes, and Byetta is the first approved GLP-1 analog. The launch of Byetta has been, and should continue to be, the most significant driver of value in Amylin shares. Notably, the biological action of GLP-1 is either directly or indirectly associated with a significant number of drugs in clinical development."
William Blair & Company, L.L.C. ( http://www.williamblair.com ) is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, we have been committed to helping clients achieve their financial objectives. William Blair & Company has offices in Chicago, Hartford, London, San Francisco, Tokyo,
Vaduz, and Zurich.
William Blair & Company, L.L.C. has received compensation for investment banking services from the company within the past 12 months, or expects to receive or intends to seek compensation for investment banking services in the next 3 months.
William Blair & Company, L.L.C. is a market maker in the security of this company and may have a long or short position.
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/03-21-2006/0004324327&...
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM